Ublituximab: Difference between revisions
Content deleted Content added
Juansempere (talk | contribs) link to the whole pipeline |
No edit summary |
||
Line 37: | Line 37: | ||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = |
||
| KEGG = D11243 |
|||
<!-- Chemical data --> |
<!-- Chemical data --> |
||
| chemical_formula = |
| chemical_formula = |
Revision as of 04:35, 27 November 2018
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | CD20 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG | |
(what is this?) (verify) |
Ublituximab is an immunomodulator. It binds to CD20.[1]
It is currently in Phase 3 clinical trials for multiple sclerosis.[2]
It is also in Phase 2 clinical trials for chronic lymphocytic leukemia.
See also
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- ^ https://clinicaltrials.gov/ct2/show/NCT03277261